By LumaLex Law | November 26
Sponsor banks are pulling Mastercard acceptance from research-use-only (RUO) peptide merchants, and they’re doing it quickly. Portfolio-wide notices are giving merchants days, not weeks, to stop processing. Merchants who ask why are often told only that there was a “Mastercard violation” and that they should take it up with Mastercard.
Mastercard enforces its rules through its Business Risk Assessment and Mitigation (BRAM) program, and its 2026 guidance to acquirers singles out RUO peptides as a fast-growing source of violations. That guidance takes the position that a chemical sold to consumers for self-administration is a drug, regardless of what the label says, and gives acquirers a detailed checklist for distinguishing legitimate research sales from consumer drug sales.
One of the biggest risks for merchants is not simply losing the ability to accept credit cards. It’s being reported to Mastercard’s MATCH database, which can affect both the business and its owners for years.
The card networks are now reading peptide websites much the same way FDA does. If you followed FDA’s August warning letters, you already know what they’re looking for. The difference is speed. FDA sends a warning letter and gives you fifteen business days to respond. A card network acts through your bank, and you may not hear about it until your account is already closed.
Here are the five takeaways that matter for anyone in this space who still accepts cards.
1. A “Category Exit” Notice and a BRAM Finding Can Arrive Together, and Only One of Them Is About You
Enforcement is running on two tracks. On the first, sponsor banks are discontinuing Mastercard acceptance across their entire RUO peptide portfolios, usually described as a business decision rather than a finding about any particular merchant. On the second, Mastercard identifies a specific website, sends a notice to the acquiring bank, and gives the bank a short window to investigate, cut off the activity, and report back.
The merchant is not copied on that notice. Nothing in Mastercard’s rules requires the bank to share it, and banks often don’t, at least not promptly. A merchant can receive a portfolio-wide notice that its Mastercard processing is ending for business reasons while its bank is holding a merchant-specific finding that names its URL.
If your processor tells you Mastercard acceptance is ending, ask in writing whether any card-network communication specifically names your business. Understanding the distinction is important because a category-wide exit does not necessarily mean your business has committed a reportable violation or will be placed on MATCH.
2. MATCH Is the Real Penalty, and the Clock Runs on the Bank’s Timeline, Not Yours
Losing a payment processor is one thing. Being placed on MATCH can have consequences that extend well beyond your current business.
MATCH stands for Member Alert to Control High-Risk Merchants, a database maintained by Mastercard that acquiring banks check before opening new merchant accounts. Visa maintains a similar system. When a bank terminates a merchant account for certain reasons, such as card-network rule violations, excessive chargebacks, or fraud, it may be required to report the merchant to MATCH.
Under Mastercard’s rules, an acquirer that terminates a merchant and has reason to believe a qualifying condition exists must report it within five calendar days. That window can open when the bank first learns of the issue, not when it notifies you.
A MATCH listing isn’t technically a ban on accepting credit cards, but in practice, it can function much like one:
- A listing generally remains in the database for five years.
- Most mainstream banks and payment processors will decline a listed business, and some may close existing accounts when they discover a listing.
- High-risk payment processors willing to work with a listed merchant typically charge significantly higher rates and require substantial reserves.
MATCH does not just affect the business. It can affect its owners personally. The database also identifies the business’s reported principals, including owners and officers named on the merchant application. Individuals who sign as owners or personal guarantors may be personally exposed to a listing. If an individual is reported to MATCH, that listing can follow them to future businesses when they apply for payment processing.
Mastercard does not independently verify every listing for accuracy, and early removal generally requires action by the bank that submitted it. Most merchant agreements also contain the merchant’s advance consent to MATCH reporting and a release of the bank.
The consequences can extend to other existing businesses. Acquirers periodically re-screen their merchants against MATCH, so a single listing can trigger account closures at other banks where a merchant or listed principal was previously in good standing.
3. Mastercard Now Applies the Same Intended-Use Test as FDA
Mastercard’s guidance tracks FDA’s approach closely. “Research use only” and “not for human consumption” disclaimers are treated as inconclusive, and the absence of health claims on a website does not settle the issue. What matters is the objective evidence of how the product is actually sold and to whom, an approach that closely resembles the intended-use framework under 21 C.F.R. § 201.128 that FDA applied in its March 2026 and August 2026 warning letters.
The similarities become clear when you look at the specifics. FDA treated bacteriostatic water sold alongside peptides as an unapproved drug in its own right, while Mastercard lists reconstitution supplies as a red flag. FDA identified coded products by molecule without difficulty, and Mastercard flags product names altered to avoid keyword detection.
A website that could draw an FDA warning letter may also draw a BRAM finding, and the BRAM finding could come first.
This has become a significant issue for RUO peptide sellers in 2026. Mastercard has stepped up enforcement against merchants whose websites and sales practices indicate that their products are not genuinely being sold for research purposes. As a result, banks have been closing merchant accounts and reporting qualifying violations to MATCH.
Classification is part of this, too. Mastercard expects RUO peptide merchants to be coded under Merchant Category Code (MCC) 5122 (Drugs, Drug Proprietaries, and Druggists’ Sundries). A bank asking to change your MCC is not simply a formality, and declining an accurate classification can create additional problems.
4. The Fines Land on the Merchant
BRAM assessments are levied against the acquiring bank, and they can be substantial, with separate exposure for late MATCH reporting or an incomplete response to Mastercard. Most merchant processing agreements allow the bank and processor to pass those amounts through to the merchant, typically by offsetting them against reserves or debiting operating accounts. Some high-risk addenda impose fixed noncompliance fees on top of those amounts.
Merchants should be prepared for their reserves to be held for months after termination. Timing also matters. Mastercard’s process favors acquirers that shut down flagged activity promptly, so a merchant that follows processing instructions immediately may be in a better position to contest assessments later charged to it.
5. Switching Processors and Suing the Bank Are Not Exit Strategies
Every Mastercard acquirer receives the same guidance, which is why processors that once specialized in this category are exiting it or re-underwriting their portfolios. Moving to a new processor without addressing the underlying compliance issues simply moves the problem, and a MATCH inquiry will likely reveal the merchant’s history.
One particularly important issue is the use of family members or other individuals to obtain payment processing.
Family members are not automatically placed on MATCH simply because they’re related to a listed merchant or business owner. However, there are two situations that business owners should avoid:
- Putting a family member’s name on a merchant account. If you put a child’s or another person’s name on an account as the owner or merchant of record, that person becomes exposed as a principal. If the account is terminated for a reportable reason, they could be listed individually, potentially affecting their ability to obtain payment processing for their own businesses for years.
- Using someone else’s account to get around a processing problem. Banks look at who actually owns and controls a business and can link accounts through addresses, bank accounts, tax IDs, and websites. Opening an account in someone else’s name to conceal your involvement in a business you control, or processing your sales through another company’s merchant account without authorization, can be treated as transaction laundering. That can itself be grounds for a MATCH listing and may create fraud exposure for everyone involved.
Litigation may not offer an easy solution either. Merchant agreements give banks broad discretion to terminate and usually include consent to MATCH reporting. In Peptide Tech LLC v. Avidia Bank, a federal court in Massachusetts dismissed every claim a peptide seller brought against the bank that placed it on MATCH, including its contract, tortious interference, and Lanham Act theories.
The stakes outside of payment processing also continue to rise, as the Piper sentencing made clear.
Mastercard’s Red Flags, as a Self-Audit
Mastercard’s guidance gives acquirers a list of indicators that peptides are being sold as unregulated drugs rather than for legitimate research. We have organized them below as a checklist. No single item is decisive, but acquirers are told to look at the whole picture, and you should too.
SELF-AUDIT: MASTERCARD’S RED FLAGS FOR RUO PEPTIDE MERCHANTS
If your business checks any of these boxes, assume your acquirer and Mastercard will notice.
|
MARKETING AND CLAIMS |
|
|
☐ |
Promotional claims, express or implied, on your website, social media, email, or messaging channels such as Telegram or WhatsApp |
|
☐ |
Therapeutic benefit language, such as references to tissue repair, digestion, sleep, memory, muscle, inflammation, or weight, or to diseases like obesity |
|
☐ |
Reviews and testimonials, on your site or in blogs and social posts that reference you |
|
☐ |
Legitimacy signals, such as references to FDA-registered facilities or displayed testing certificates used to suggest safety |
|
PRODUCTS AND PRESENTATION |
|
|
☐ |
FDA-approved drugs labeled RUO, including GLP-1 receptor agonists |
|
☐ |
Well-known peptides with an established consumer following (BPC-157 is a common example) |
|
☐ |
Abbreviated or altered product names that appear designed to avoid keyword detection |
|
☐ |
Lyophilized powders sold for reconstitution, in vials sized for an individual dose |
|
☐ |
Reconstitution supplies, including bacteriostatic water, sterile water for injection, or syringes |
|
☐ |
Reconstitution, dosing, or administration guidance, whether in product descriptions, FAQs, calculators, or social content |
|
SALES PRACTICES AND CUSTOMERS |
|
|
☐ |
Small orders, such as one to five vials per purchase |
|
☐ |
Sales to individuals or shipments to home or personal addresses |
|
☐ |
Age-verification prompts, which suggest you know your buyers are individual consumers |
|
☐ |
Self-attestations that the buyer is a researcher or a medical provider |
|
☐ |
Memberships, subscriptions, or enrollment programs |
|
☐ |
Promotions and discounts, such as site-wide sales or buy-two-get-one offers |
|
WHAT MASTERCARD TREATS AS EVIDENCE OF GENUINE RESEARCH SALES |
|
|
✓ |
Purchase-order requirements |
|
✓ |
Bulk or large-quantity orders |
|
✓ |
Sales and shipments to universities, corporations, or laboratories equipped to conduct in vitro research |
Organized from Mastercard’s 2026 BRAM guidance to acquirers. Illustrative, not exhaustive; no single item is determinative.
What Operators Should Do Now
Avoiding a MATCH listing starts with addressing the underlying reasons a merchant account could be terminated. For RUO peptide companies, that means ensuring the business genuinely operates as a research supply company, rather than relying on website disclaimers alone.
Website content can form the basis of a BRAM finding, and your business can be assessed at any time without prior notice.
At minimum:
- Audit the full digital footprint against the checklist above: product pages, blog and SEO content, FAQs, calculators, outbound links, email and SMS, affiliate copy, and social media.
- Compare your merchant application to how you actually operate. If it says your sales are business-to-business, make sure they are.
- Confirm that your MCC accurately reflects what you sell.
- Replace checkbox attestations with genuine research-sales controls: verified institutional customers, purchase orders, appropriate quantities, and shipment to qualified facilities.
- Review what you sell alongside your peptide SKUs, including bacteriostatic water, syringes, and reconstitution resources.
- Monitor chargebacks and address payment disputes promptly, as excessive chargebacks can independently trigger MATCH reporting.
- Review who is named on your merchant account as an owner, officer, principal, or personal guarantor. Make sure the account accurately reflects the business’s actual ownership and control.
- Read your merchant agreement for fine pass-through provisions, noncompliance fees, reserve rights, MATCH consent, notice requirements, and dispute resolution.
- Preserve a record of your website as it currently stands and archive it regularly.
- Build a lawful contingency plan for losing card acceptance, and evaluate whether the business model itself needs to change. Do not use another person’s identity or merchant account to circumvent processing restrictions.
These steps cannot guarantee that a bank will continue processing payments for your business, but they can help reduce the risk of a termination that results in a MATCH listing.
If a Notice Arrives
- Read it for what it does and does not say. A portfolio-wide change and a merchant-specific finding call for different responses.
- Follow processing instructions immediately, and document the date you stopped.
- Ask in writing, preferably through counsel, whether any card-network notice or investigation names your business. Request the case number, the basis for the finding, any MATCH report and reason code, the identities of any listed principals, and any assessments attributed to you. If the bank will not share network documents, ask for a summary.
- Do not argue the merits before you have the record. Statements that contradict your own website or business practices can create additional problems.
- Preserve everything: the website as it stands, every notice, every email, and notes from every call.
- Watch your reserve. Request documentation before any assessment is charged, and review whether the amounts relate to your conduct or the bank’s own obligations.
- If you have already been listed, focus on what can still change: the accuracy of the reason code and listed principals, reserve releases, and assessment exposure. Early removal is rare.
- Answer every future processing application truthfully, including questions about prior terminations and MATCH listings.
Card-network deadlines run in days, and the first written exchange with your bank can influence what happens next. Having legal counsel involved early can help you understand your exposure, protect your interests, and avoid mistakes that could affect your ability to obtain payment processing in the future.
LumaLex Law advises peptide companies, compounding pharmacies, and telehealth platforms on FDA regulatory exposure, card-network compliance, and merchant processing disputes, including terminations, MATCH listings, and reserve and assessment issues. If you would like to discuss your processing relationship, understand your risk of being placed on MATCH, or have your website reviewed, get in touch.
This article discusses card-network guidance and public enforcement actions for general informational purposes. It is not legal advice regarding any specific set of facts and does not create an attorney-client relationship.



